arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

VERU INC.

VERU
$2.45 ▼ -0.05 (-2.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

VERU INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $35.9M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -106.7% ↘
FCF / Share $-2.05 ↘
Trailing P/E —
Price / Book 2.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$16.89M
↑ +3.6% —
Net Income Profit after all expenses
$-22.73M
↑ +39.9% —
Operating Margin Operating profit as % of sales
-218.6%
↓ -3.4% —
FCF / Share Free cash flow per share
$-2.05
↓ -1166.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
6
Financial Health
15
Cash Quality
76

Dividend History

Dividend / share · sourced from SEC filings
$0.21 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters